Ibrutinib produces rapid and endurable respons... - CLL Support

CLL Support

22,474 members38,608 posts

Ibrutinib produces rapid and endurable responses. PFS and DOR not reached at up to 44 months -Steven Coutre's Lymphoma & Myeloma 2015 update

AussieNeil profile image
AussieNeilAdministrator
8 Replies

'Long-term follow-up of single-agent ibrutinib at the approved dose of 420 mg daily confirms that the Bruton’s tyrosine kinase inhibitor produces rapid and durable responses in patients with chronic lymphocytic leukemia (CLL), according to an update presented at Lymphoma & Myeloma 2015.

At up to 44 months of follow-up, the median duration of response (DOR) and progression-free survival (PFS) have not yet been reached.

At 30 months, the PFS rate was 96% for treatment-naïve patients and 76% for relapsed or refractory patients. Patients with del 17p had a median PFS of 32.4 months.

“Virtually all the patients do respond to treatment,” said Steven Coutre, MD, of Stanford University School of Medicine in California.'

Full article from Hematology Times (free registration)

hematologytimes.com/p_artic...

Neil

Written by
AussieNeil profile image
AussieNeil
Administrator
To view profiles and participate in discussions please or .
Read more about...
8 Replies
Justasheet1 profile image
Justasheet1

Neil,

Great data.

Jeff

AussieNeil profile image
AussieNeilAdministrator

And in related news, if you've been on Ibrutinib for over a year and your lymphocyte count (ALC) remains high, it doesn't mean that you aren't doing well on Ibrutinib, it's just that you have a different flavour of CLL than other patients, or as this Blood Journal paper puts it:"Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy"

bloodjournal.org/content/12...

Thanks to member lapermone for bringing this article to my attention.

Neil

charliegirl profile image
charliegirl in reply to AussieNeil

Many thanks for posting this info, Neil

Excellent news for those of us who are on ibrutinib.

Charlie Girl

Jilltap profile image
Jilltap in reply to AussieNeil

Thank you. I am a slow responder and this info is helpful

manzelka profile image
manzelka

This is good to see as my husband is to start taking Ibrutinib tomorrow.

I am apprehensive about side effects.

nobby00 profile image
nobby00 in reply to manzelka

my husband is due to start next ,very hopeful keep us informed

splashsplash3 profile image
splashsplash3

Thanks for this posting Neil, really good to hear that the good news continues past the four year point. Can we use the 'C' word yet - CURE?

I have only been on Ibrutinib on the NHS for six weeks after two previous relapses and two chemo courses of FCR.

After only two hours of taking the first Ibrutinib pill I began to feel a lot better and my Leukaemia cells started to drop virtually immediately and they continue to fall. So far I have no side effects even though after chemo I was expecting the worst.

Now after only a few weeks I have a 'normal' plus amount of energy and I can even cycle up hills and sprint up stairs.

Just a shame Ibrutinib is so expensive because it's the most amazing drug, quite magical.

tpetro profile image
tpetro

Do we have any sense when Ibrutinib will be available as frontline treatment in CLL?

You may also like...

Adding Venetoclax to Obinutuzumab Prolongs Progression-Free Survival in Previously Untreated CLL

higher rates of progression-free survival (PFS) at 24 months, compared with patients who received...

Duvelisib Dosing Modification Does Not Compromise Efficacy in Heavily Pretreated CLL/SLL

PI3K inhibitor led to a superior median progression-free survival (PFS) compared with ofatumumab...

Progression Free Survival (PFS) post Discontinuation of Ibrutinib in E1912 Trial

iwCLL this year - \\"patients who stopped ibrutinib for toxicity had a median PFS from the time...

Time-Limited Triplet Emerges as a Potential Standard in Relapsed/Refractory CLL

disease (uMRD) and complete responses (CRs) in patients with relapsed/refractory CLL....

FCR vs imbruvica first line

3 year PFS. The blue line is treatment free, and the yellow is relapsed/refractory patients. 95.8%